Hospital Sultanah Bahiyah | Clinical Research Centre

Research site

(Unclaimed)

Location

Clinical Research Centre (CRC) Hospital Sultanah Bahiyah, Alor Setar, Kedah, Malaysia

Site insights

Top conditions

Top treatments

Upadacitinib

ABT-494

Relamorelin

Ziltivekimab

Semaglutide

JNJ-56136379

Apixaban

Luspatercept

Trimethoprim

Pelabresib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 46 total trials

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 (U-ENDURE)

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting

Crohn's Disease

Drug: Placebo for Upadacitinib

Drug: Upadacitinib

A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation (ATHENA)

The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either...

Enrolling

Systemic Inflammation

Heart Failure

Drug: Placebo

Drug: Ziltivekimab

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation (HERMES)

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling

Heart Failure

Drug: Placebo

Drug: Ziltivekimab

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT) (ENERGIZE)

The primary purpose of this study is to compare the effect of mitapivat versus placebo on anemia in participants with alpha- or beta-non-transfusion...

Active, not recruiting

Non-Transfusion-dependent Alpha-Thalassemia

Non-Transfusion-dependent Beta-Thalassemia

Drug: Placebo Matching Mitapivat

Drug: Mitapivat

A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD)

The purpose of this study is to evaluate the efficacy of JNJ-78934804 at Week 48 compared to guselkumab and golimumab.

Active, not recruiting

Crohn's Disease

Biological: JNJ-78934804

Biological: Golimumab

A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation (LIBREXIA-AF)

The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-cent...

Enrolling

Atrial Fibrillation

Drug: Apixaban Placebo

Drug: Milvexian

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following participants:* Participants rec...

Enrolling

Beta-thalassemia

Myelodysplastic Syndromes (MDS)

Drug: Luspatercept

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) (U-ACHIEVE)

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting

Ulcerative Colitis (UC)

Drug: Placebo

Drug: Upadacitinib (ABT-494)

ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

The research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivek...

Enrolling

Acute Myocardial Infarction (AMI)

Cardiovascular Risk

Drug: Ziltivekimab

Drug: Placebo

LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ELEVATE)

This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults wit...

Active, not recruiting

Idiopathic Pulmonary Fibrosis

Drug: Deupirfenidone

Drug: Placebo

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that...

Active, not recruiting

Myelofibrosis

Post-essential Thrombocythemia Myelofibrosis

Drug: Placebo

Drug: Pelabresib

Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK)

The TRACK trial is an investigator-initiated, multicentre, prospective, randomised, quadruple-blind (participant, healthcare provider, data collector...

Enrolling

Chronic Kidney Diseases

Dialysis-dependent Kidney Failure

Drug: Rivaroxaban 2.5 Mg Oral Tablet

Other: Placebo

Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia

The study is conducted in patients with functional dyspepsia or chronic gastritis. The purpose of this study is to:* assess whether the dose of Itopr...

Enrolling

Functional Dyspepsia

Drug: Itopride Hydrochloride 150 mg extended release tablets

Drug: Itopride Hydrochloride 50 mg film coated tablets

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Enrolling

Chronic Kidney Disease

Inflammation

Drug: Placebo (Ziltivekimab B)

Drug: Placebo (Ziltivekimab C)